RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 Recombinant Human Coagulation Factor IX Fc Fusion Protein Effective in Kids B-LONG Study
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 21
SP 6
OP 7
DO 10.1177/1559897715599368
UL http://mdc.sagepub.com/content/15/21/6.2.abstract
AB The Kids B-LONG study was conducted to evaluate the pharmacokinetics, safety, and efficacy of recombinant human coagulation factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B. rFIXFc is considered safe and efficacious for prophylaxis and the control of acute bleeding in children age < 12 years.